MedTrace Logo

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression

NCT04491994 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2020-08-21

Study results available
· View outcomes & findings →

Summary

Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.

Condition or disease :I COVID-19 ntervention/treatment :Drug: Hydroxychloroquine Sulfate Phase: Phase III

Conditions

  • Covid19
  • Progression

Interventions

DRUG

HCQ

Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days

Sponsors & Collaborators

  • Pak Emirates Military Hospital

    collaborator OTHER

  • UNICEF

    lead OTHER

Principal Investigators

  • Imran m Fazal, FCPS · Pak Emirates Military Hospital (PEMH) Rawalpindi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04491994 on ClinicalTrials.gov